NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021

• DOI: 10.6004/jnccn.2021.0002
• Publication Date: 2021-01-06T20:49:23Z
• Authors: Daniel A. Pollyea; Dale Bixby; Alexander Perl; Vijaya Raj Bhatt; Jessica K. Altman; Frederick R. Appe...; Marcos de Lima; Amir T. Fathi; James M. Foran; Ivana Gojo; Aric C. Hall; Meagan Jacoby; Jeffrey Lancet; Gabriel Mannis; Guido Marcucci; Michael G. Martin; Alice Mims; Jadee Neff; Reza Nejati; Rebecca Olin; Mary-Elizabeth Pe...; Thomas Prebet; Amanda Przespolewski; Dinesh Rao; Farhad Ravandi-Ka...; Paul J. Shami; Richard M. Stone; Stephen A. Strick...; Kendra Sweet; Pankit Vachhani; Matthew Wieduwilt; Kristina M. Gregory; Ndiya Ogba; Martin S. Tallman
• Keywords: Venetoclax

The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or yielded new information regarding factors prognostic importance, are intended aid physicians decision-making. These Insights focus recent select updates Guidelines, including familial genetic alterations AML, postinduction postremission strategies low-risk acute promyelocytic leukemia favorable-risk principles surrounding use venetoclax-based therapies, considerations patients who prefer not receive blood transfusions during treatment.